Predisposing variants in PMS2 confer a low prevalence of cancer due to the protein's genetic redundancy (11%–20% lifetime colorectal cancer risk by age 70) (Senter et al., 2008; ten Broeke et al., 2015). This evidence concerns the gene PMS2 and cancer.